Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Using Multi-omics

Multicenter Cohort Study on Predicting Bronchiectasis Progression, Complications, and Prognosis Through Multimodal Integration of Radiomics, Clinical Features, and Lung Microbiota

Bronchiectasis is a heterogeneous condition with diverse etiologies and clinical manifestations. Its progression involves a vicious cycle of airway inflammation, recurrent infection, and structural damage, leading to persistent symptoms and declining lung function. Current management focuses on airway clearance and antibiotics, with no disease-modifying therapies available. Recognizing this heterogeneity is crucial for advancing targeted treatments and precision medicine.

Radiomics converts medical images into mineable data to reveal underlying pathophysiology. While applied in other respiratory diseases, its potential in bronchiectasis remains underexplored. Both radiomics and the lung microbiome are independently linked to disease severity in conditions like COPD, but their interplay is unclear. Integrating these modalities with clinical data could unlock novel insights, identify new therapeutic targets, and improve diagnostic and prognostic models.

However, few studies have investigated multimodal models combining radiomics, microbiome, and clinical features to predict outcomes in bronchiectasis. To address this gap, we designed a multicenter, retrospective study. It will analyze data from patients diagnosed between January 2020 and July 2025 to evaluate the combined value of radiomics, microbial features, and clinical parameters in diagnosing and predicting the progression of bronchiectasis.

Study Overview

• Status: Completed
• Conditions: Bronchiectasis Adult; Radiomics

• Study Type: Observational
• Enrollment (Actual): 2000

Contacts and Locations

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 21000
      • The First Affiliated Hospital of Nanjing Medical University，

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with a diagnosis of bronchiectasis established by high-resolution CT (HRCT) of the chest and its corresponding radiology report.

Description

Inclusion Criteria:

• ① Diagnosis of bronchiectasis;

  • Availability of both raw high-resolution computed tomography (HRCT) chest images and the corresponding radiology report; ③ Age ≥ 18 years.

Exclusion Criteria:

• ① Incomplete clinical data;

  • Absence of chest CT imaging studies and reports; ③ Other patients deemed ineligible for enrollment at the investigator's discretion.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Bronchiectasis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
death	2025.7

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital with Nanjing Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2020
• Primary Completion (Actual): June 30, 2025
• Study Completion (Actual): July 31, 2025

Study Registration Dates

• First Submitted: November 24, 2025
• First Submitted That Met QC Criteria: November 24, 2025
• First Posted (Estimated): December 4, 2025

Study Record Updates

• Last Update Posted (Estimated): December 4, 2025
• Last Update Submitted That Met QC Criteria: November 24, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Other Study ID Numbers: 2025-SR-695

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No